Portola Pharmaceuticals Company Profile (NASDAQ:PTLA)

About Portola Pharmaceuticals (NASDAQ:PTLA)

Portola Pharmaceuticals logoPortola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PTLA
  • CUSIP: N/A
  • Web: www.portola.com
Capitalization:
  • Market Cap: $3.24501 billion
  • Outstanding Shares: 57,020,000
Average Prices:
  • 50 Day Moving Avg: $38.42
  • 200 Day Moving Avg: $32.81
  • 52 Week Range: $15.68 - $57.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -14.79
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $32.37 million
  • Price / Sales: 95.84
  • Book Value: $2.84 per share
  • Price / Book: 19.16
Profitability:
  • EBIDTA: ($242,850,000.00)
  • Net Margins: -759.21%
  • Return on Equity: -106.68%
  • Return on Assets: -69.77%
Debt:
  • Debt-to-Equity Ratio: 0.60%
  • Current Ratio: 6.81%
  • Quick Ratio: 6.81%
Misc:
  • Average Volume: 717,009 shs.
  • Beta: 1.36
  • Short Ratio: 8.9
 

Frequently Asked Questions for Portola Pharmaceuticals (NASDAQ:PTLA)

What is Portola Pharmaceuticals' stock symbol?

Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

How were Portola Pharmaceuticals' earnings last quarter?

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) issued its quarterly earnings results on Monday, May, 8th. The company reported ($0.74) EPS for the quarter, beating analysts' consensus estimates of ($1.20) by $0.46. The firm had revenue of $5.12 million for the quarter, compared to analysts' expectations of $4.21 million. Portola Pharmaceuticals had a negative return on equity of 106.68% and a negative net margin of 759.21%. The business's revenue for the quarter was down 37.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.15) EPS. View Portola Pharmaceuticals' Earnings History.

Where is Portola Pharmaceuticals' stock going? Where will Portola Pharmaceuticals' stock price be in 2017?

8 brokers have issued twelve-month price objectives for Portola Pharmaceuticals' stock. Their predictions range from $27.00 to $78.00. On average, they anticipate Portola Pharmaceuticals' stock price to reach $61.50 in the next twelve months. View Analyst Ratings for Portola Pharmaceuticals.

What are analysts saying about Portola Pharmaceuticals stock?

Here are some recent quotes from research analysts about Portola Pharmaceuticals stock:

  • 1. Cowen and Company analysts commented, "Portola hosted an investor event at the American College of Cardiology (ACC) annual meeting. Data from betrixaban's APEX Phase III and AndexXa's ANNEXA-4 Phase IV trials were discussed. Investors were keenly focused on examining the APEX clinical data ahead of betrixaban's June PDUFA. While risk remains, we think approval is more likely than not. We remain at Outperform." (3/20/2017)
  • 2. According to Zacks Investment Research, "Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. " (1/18/2017)

Who are some of Portola Pharmaceuticals' key competitors?

Who are Portola Pharmaceuticals' key executives?

Portola Pharmaceuticals' management team includes the folowing people:

  • Hollings C. Renton III, IndependentChairman of the Board
  • William Lis, Chief Executive Officer, Director
  • Mardi C. Dier, Chief Financial Officer, Executive Vice President
  • John T. Curnutte M.D. Ph.D., Executive Vice President - Research & Development
  • Tao Fu, Executive Vice President, Chief Commercial and Business officer
  • Jeffrey W. Bird M.D. Ph.D., Independent Director
  • Laura A. Brege, Independent Director
  • Dennis M. Fenton Ph.D., Independent Director
  • Charles J. Homcy M.D., Independent Director
  • John H. Johnson, Independent Director

Who owns Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (9.61%), Vanguard Group Inc. (8.16%), BlackRock Inc. (7.13%), FMR LLC (6.90%), State Street Corp (3.49%) and JPMorgan Chase & Co. (1.88%). Company insiders that own Portola Pharmaceuticals stock include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, Fullerton Management Pte Ltd, Jeffrey W Bird, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Institutional Ownership Trends for Portola Pharmaceuticals.

Who sold Portola Pharmaceuticals stock? Who is selling Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Emerald Advisers Inc. PA, UBS Group AG, JPMorgan Chase & Co., Emerald Mutual Fund Advisers Trust, Wellington Management Group LLP, Prudential Financial Inc. and Pictet Asset Management Ltd.. Company insiders that have sold Portola Pharmaceuticals stock in the last year include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, Mardi Dier, Tao Fu and William Lis. View Insider Buying and Selling for Portola Pharmaceuticals.

Who bought Portola Pharmaceuticals stock? Who is buying Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Bogle Investment Management L P DE, FMR LLC, Vanguard Group Inc., Teachers Advisors LLC, Rosenblum Silverman Sutton S F Inc. CA, UBS Asset Management Americas Inc. and Highbridge Capital Management LLC. Company insiders that have bought Portola Pharmaceuticals stock in the last two years include Fullerton Management Pte Ltd and Jeffrey W Bird. View Insider Buying and Selling for Portola Pharmaceuticals.

How do I buy Portola Pharmaceuticals stock?

Shares of Portola Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Portola Pharmaceuticals' stock price today?

One share of Portola Pharmaceuticals stock can currently be purchased for approximately $54.41.


MarketBeat Community Rating for Portola Pharmaceuticals (NASDAQ PTLA)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  163 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  232
MarketBeat's community ratings are surveys of what our community members think about Portola Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Portola Pharmaceuticals (NASDAQ:PTLA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $61.50 (13.03% upside)

Analysts' Ratings History for Portola Pharmaceuticals (NASDAQ:PTLA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/26/2017Credit Suisse GroupReiterated RatingNeutral$39.00 -> $58.00MediumView Rating Details
6/26/2017Morgan StanleyBoost Price TargetOverweight$50.00 -> $70.00LowView Rating Details
6/26/2017Oppenheimer Holdings, Inc.Boost Price TargetOutperform$46.00 -> $66.00HighView Rating Details
6/26/2017Cowen and CompanyBoost Price TargetOutperform$45.00 -> $70.00HighView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
6/26/2017Citigroup Inc.Boost Price TargetBuy$51.00 -> $78.00MediumView Rating Details
2/24/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
1/11/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$22.00 -> $27.00N/AView Rating Details
(Data available from 6/28/2015 forward)

Earnings

Earnings History for Portola Pharmaceuticals (NASDAQ:PTLA)
Earnings by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)
Earnings History by Quarter for Portola Pharmaceuticals (NASDAQ PTLA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($1.20)($0.74)$4.21 million$5.12 millionViewListenView Earnings Details
2/28/2017Q4 2016($1.12)($0.95)$3.98 million$13.70 millionViewListenView Earnings Details
11/7/2016Q3($1.10)($1.64)$4.10 million$9.30 millionViewListenView Earnings Details
8/9/2016Q216($1.20)($1.02)$4.38 million$4.23 millionViewListenView Earnings Details
5/5/2016Q1($1.06)($1.15)$7.91 million$8.30 millionViewListenView Earnings Details
2/26/2016Q415($1.12)($1.23)$2.43 million$4.40 millionViewListenView Earnings Details
8/4/2015Q215($1.07)($1.12)$2.30 million$2.39 millionViewListenView Earnings Details
5/6/2015Q115($1.09)($0.95)$2.60 million$2.36 millionViewListenView Earnings Details
3/2/2015Q414($0.90)($0.82)$2.40 million$2.41 millionViewListenView Earnings Details
11/10/2014Q314($0.92)($0.86)$2.73 million$2.40 millionViewListenView Earnings Details
8/6/2014Q214($0.79)($0.76)$2.44 million$2.42 billionViewListenView Earnings Details
5/12/2014Q114($0.72)($0.75)$1.81 million$2.40 millionViewListenView Earnings Details
2/27/2014Q4($0.57)($0.63)$2.17 million$2.10 millionViewListenView Earnings Details
8/15/2013($0.72)($1.47)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Portola Pharmaceuticals (NASDAQ:PTLA)
2017 EPS Consensus Estimate: ($5.38)
2018 EPS Consensus Estimate: ($3.55)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.30)($1.12)($1.21)
Q2 20172($1.53)($1.06)($1.30)
Q3 20172($1.69)($1.34)($1.52)
Q4 20172($1.58)($1.14)($1.36)
Q1 20181($1.23)($1.23)($1.23)
Q2 20181($1.04)($1.04)($1.04)
Q3 20181($0.74)($0.74)($0.74)
Q4 20181($0.54)($0.54)($0.54)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Portola Pharmaceuticals (NASDAQ:PTLA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Portola Pharmaceuticals (NASDAQ:PTLA)
Insider Ownership Percentage: 4.90%
Institutional Ownership Percentage: 85.24%
Insider Trades by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)
Institutional Ownership by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)
Insider Trades by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/26/2017Tao FuEVPSell7,000$57.14$399,980.00View SEC Filing  
6/23/2017Charles J. HomcyDirectorSell120,803$53.06$6,409,807.18View SEC Filing  
6/1/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell1,700,000$34.40$58,480,000.00View SEC Filing  
6/1/2017Jeffrey W BirdDirectorBuy119,442$31.85$3,804,227.70View SEC Filing  
4/11/2017William LisCEOSell6,750$36.06$243,405.00View SEC Filing  
4/10/2017Tao FuEVPSell1,097$36.97$40,556.09View SEC Filing  
3/15/2017Charles J. HomcyDirectorSell50,000$40.06$2,003,000.00View SEC Filing  
3/15/2017Mardi DierVPSell10,235$40.02$409,604.70View SEC Filing  
5/2/2016William LisCEOSell5,675$23.86$135,405.50View SEC Filing  
12/9/2015Fullerton Management Pte LtdMajor ShareholderBuy750,000$48.00$36,000,000.00View SEC Filing  
9/18/2015Charles J. HomcyDirectorSell40,067$56.25$2,253,768.75View SEC Filing  
9/18/2015Mardi DierCFOSell8,912$55.00$490,160.00View SEC Filing  
7/15/2015John T CurnutteEVPSell10,000$50.00$500,000.00View SEC Filing  
7/15/2015William LisCEOSell50,000$50.00$2,500,000.00View SEC Filing  
7/13/2015Charles J HomcyDirectorSell50,000$48.00$2,400,000.00View SEC Filing  
7/2/2015William LisCEOSell15,000$45.60$684,000.00View SEC Filing  
7/1/2015William LisCEOSell30,000$45.01$1,350,300.00View SEC Filing  
6/30/2015William LisCEOSell15,000$44.48$667,200.00View SEC Filing  
6/29/2015Charles J HomcyDirectorSell100,000$43.78$4,378,000.00View SEC Filing  
6/22/2015John T CurnutteEVPSell10,000$47.50$475,000.00View SEC Filing  
6/16/2015John T CurnutteEVPSell10,000$45.00$450,000.00View SEC Filing  
6/8/2015Mardi DierCFOSell16,119$43.00$693,117.00View SEC Filing  
5/29/2015John T CurnutteEVPSell10,000$42.50$425,000.00View SEC Filing  
5/28/2015John T CurnutteEVPSell10,000$40.30$403,000.00View SEC Filing  
5/27/2015Mardi DierCFOSell6,076$41.00$249,116.00View SEC Filing  
5/12/2015Mardi DierCFOSell13,290$37.88$503,425.20View SEC Filing  
5/11/2015Hollings RentonDirectorSell10,520$38.33$403,231.60View SEC Filing  
5/11/2015Mardi DierCFOSell13,674$38.21$522,483.54View SEC Filing  
4/30/2015William LisCEOSell45,000$35.60$1,602,000.00View SEC Filing  
2/23/2015Charles J HomcyDirectorSell20,000$40.00$800,000.00View SEC Filing  
2/23/2015John T CurnutteEVPSell10,000$40.00$400,000.00View SEC Filing  
2/23/2015Mardi DierCFOSell5,692$39.95$227,395.40View SEC Filing  
2/18/2015John T CurnutteEVPSell10,000$37.50$375,000.00View SEC Filing  
2/17/2015Charles J HomcyDirectorSell20,000$36.00$720,000.00View SEC Filing  
2/17/2015John T CurnutteEVPSell10,000$35.00$350,000.00View SEC Filing  
2/13/2015Charles J HomcyDirectorSell20,000$34.05$681,000.00View SEC Filing  
2/13/2015John T CurnutteEVPSell10,000$32.50$325,000.00View SEC Filing  
1/28/2015Charles J HomcyDirectorSell19,700$30.00$591,000.00View SEC Filing  
1/20/2015William LisCEOSell20,000$27.32$546,400.00View SEC Filing  
1/16/2015William LisCEOSell20,000$26.94$538,800.00View SEC Filing  
11/25/2014Mardi DierCFOSell1,118$28.23$31,561.14View SEC Filing  
11/20/2014William LisCEOSell40,000$26.95$1,078,000.00View SEC Filing  
11/17/2014William LisCEOSell30,000$26.69$800,700.00View SEC Filing  
10/8/2014(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy1,600,000$26.00$41,600,000.00View SEC Filing  
8/25/2014Mardi DierCFOSell5,000$26.26$131,300.00View SEC Filing  
7/25/2014Mardi DierCFOSell5,000$24.11$120,550.00View SEC Filing  
7/3/2014William LisCEOSell30,000$30.41$912,300.00View SEC Filing  
6/30/2014William LisCEOSell10,000$29.23$292,300.00View SEC Filing  
6/25/2014Mardi DierCFOSell5,000$28.52$142,600.00View SEC Filing  
6/18/2014John T CurnutteEVPSell30,000$28.33$849,900.00View SEC Filing  
6/18/2014Mardi DierCFOSell3,706$29.95$110,994.70View SEC Filing  
6/16/2014John T CurnutteEVPSell10,000$26.00$260,000.00View SEC Filing  
6/10/2014Nicholas GalakatosDirectorSell1,369$23.36$31,979.84View SEC Filing  
5/29/2014Mardi DierCFOSell5,000$23.00$115,000.00View SEC Filing  
5/27/2014William LisCEOSell30,000$20.83$624,900.00View SEC Filing  
5/21/2014William LisCEOSell10,000$19.87$198,700.00View SEC Filing  
5/16/2014Jean Jacques BienaimeDirectorSell1,000$22.03$22,030.00View SEC Filing  
4/25/2014Mardi DierCFOSell5,000$24.14$120,700.00View SEC Filing  
3/25/2014Mardi DierCFOSell5,000$25.69$128,450.00View SEC Filing  
10/22/2013Charles J HomcyDirectorSell95,962$23.75$2,279,097.50View SEC Filing  
5/28/2013(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy700,000$14.50$10,150,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Portola Pharmaceuticals (NASDAQ:PTLA)
Latest Headlines for Portola Pharmaceuticals (NASDAQ:PTLA)
Source:
DateHeadline
americanbankingnews.com logoInsider Selling: Portola Pharmaceuticals, Inc. (PTLA) EVP Sells 7,000 Shares of Stock
www.americanbankingnews.com - June 27 at 7:51 PM
americanbankingnews.com logoInsider Selling: Portola Pharmaceuticals, Inc. (PTLA) Director Sells 120,803 Shares of Stock
www.americanbankingnews.com - June 27 at 7:28 PM
benzinga.com logoPortola Pharmaceuticals: Expect Additional Upside From Here - Benzinga
www.benzinga.com - June 27 at 7:34 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Portola and AVEO
finance.yahoo.com - June 27 at 7:34 AM
finance.yahoo.com logoOppenheimer Boosts Price Target for Portola Pharmaceuticals Inc (PTLA) Following FDA Approval
finance.yahoo.com - June 27 at 7:34 AM
americanbankingnews.com logoPortola Pharmaceuticals Target of Unusually Large Options Trading (PTLA)
www.americanbankingnews.com - June 26 at 6:09 PM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) Earns "Neutral" Rating from Credit Suisse Group
www.americanbankingnews.com - June 26 at 5:50 PM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) Price Target Raised to $78.00 at Citigroup Inc.
www.americanbankingnews.com - June 26 at 12:16 PM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) Price Target Increased to $66.00 by Analysts at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - June 26 at 11:00 AM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) PT Raised to $70.00 at Morgan Stanley
www.americanbankingnews.com - June 26 at 10:27 AM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) Given Outperform Rating at Cowen and Company
www.americanbankingnews.com - June 26 at 9:04 AM
americanbankingnews.com logoPortola Pharmaceuticals' (PTLA) Outperform Rating Reiterated at William Blair
www.americanbankingnews.com - June 26 at 8:34 AM
rttnews.com logoPortola Pharmaceuticals Inc. (PTLA) Surged To A New High After FDA Approval
www.rttnews.com - June 26 at 8:06 AM
americanbankingnews.com logo$2.42 Million in Sales Expected for Portola Pharmaceuticals, Inc. (PTLA) This Quarter
www.americanbankingnews.com - June 24 at 8:52 AM
fool.com logoWhy Synchronoss Technologies, AK Steel Holding, and Portola Pharmaceuticals Jumped Today - Motley Fool
www.fool.com - June 24 at 1:07 AM
marketwatch.com logoPortola Pharma stock skyrockets after FDA approves anticoagulant for high-risk patients - MarketWatch
www.marketwatch.com - June 24 at 1:07 AM
finance.yahoo.com logoU.S. FDA Approves Bevyxxa® (betrixaban) First and Only Anticoagulant for Hospital and Extended Duration Prevention of Venous Thromboembolism (VTE) in Acutely Ill Medical Patients
finance.yahoo.com - June 23 at 8:04 PM
finance.yahoo.com logoFDA approves Portola's blood-thinning drug
finance.yahoo.com - June 23 at 8:04 PM
finance.yahoo.com logoPortola Pharma stock skyrockets after FDA approves anticoagulant for high-risk patients
finance.yahoo.com - June 23 at 8:04 PM
finance.yahoo.com logoPortola shares soar after FDA approves clot preventing drug
finance.yahoo.com - June 23 at 8:04 PM
finance.yahoo.com logoPortola Pharmaceuticals Inc.'s Green Light Sends Its Stock Soaring as Much as 51%
finance.yahoo.com - June 23 at 8:04 PM
finance.yahoo.com logoWhy Synchronoss Technologies, AK Steel Holding, and Portola Pharmaceuticals Jumped Today
finance.yahoo.com - June 23 at 8:04 PM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) Raised to "Hold" at BidaskClub
www.americanbankingnews.com - June 22 at 6:04 PM
americanbankingnews.com logo Brokerages Expect Portola Pharmaceuticals, Inc. (PTLA) Will Announce Earnings of -$1.19 Per Share
www.americanbankingnews.com - June 22 at 2:08 PM
finance.yahoo.com logoPortola Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PTLA-US : June 21, 2017
finance.yahoo.com - June 22 at 8:58 AM
nasdaq.com logoImplied Volatility Surging for Portola Pharmaceuticals (PTLA) Stock Options - Nasdaq
www.nasdaq.com - June 21 at 2:30 AM
finance.yahoo.com logoImplied Volatility Surging for Portola Pharmaceuticals (PTLA) Stock Options
finance.yahoo.com - June 21 at 2:30 AM
americanbankingnews.com logoTraders Purchase High Volume of Portola Pharmaceuticals Put Options (PTLA)
www.americanbankingnews.com - June 19 at 5:38 PM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) Given a $51.00 Price Target at Citigroup Inc.
www.americanbankingnews.com - June 19 at 12:38 AM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - June 16 at 5:00 PM
streetinsider.com logoPortola Pharma (PTLA) Presents Interim Phase 2a Data for Cerdulatinib at ICML
www.streetinsider.com - June 16 at 9:11 AM
streetinsider.com logoPortola Pharma (PTLA) Presents Interim Phase 2a Data for ... - StreetInsider.com
www.streetinsider.com - June 16 at 9:11 AM
seekingalpha.com logoPortola Pharmaceuticals: Reiterating Buy Rating Before June 24 ... - Seeking Alpha
seekingalpha.com - June 15 at 4:56 AM
finance.yahoo.com logoETFs with exposure to Portola Pharmaceuticals, Inc. : June 9, 2017
finance.yahoo.com - June 9 at 3:47 PM
americanbankingnews.com logo(Mauritius) Pte Ltd Maxwell Sells 1,700,000 Shares of Portola Pharmaceuticals Inc (PTLA) Stock
www.americanbankingnews.com - June 5 at 10:26 AM
americanbankingnews.com logoPortola Pharmaceuticals Inc (PTLA) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - June 3 at 2:02 PM
americanbankingnews.com logoInsider Buying: Portola Pharmaceuticals Inc (PTLA) Director Acquires 119,442 Shares of Stock
www.americanbankingnews.com - June 2 at 7:43 PM
americanbankingnews.com logo Analysts Anticipate Portola Pharmaceuticals Inc (PTLA) Will Post Quarterly Sales of $2.42 Million
www.americanbankingnews.com - May 31 at 2:04 PM
americanbankingnews.com logo Analysts Expect Portola Pharmaceuticals Inc (PTLA) Will Announce Earnings of -$1.19 Per Share
www.americanbankingnews.com - May 29 at 10:17 AM
finance.yahoo.com logoETFs with exposure to Portola Pharmaceuticals, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 6:30 PM
americanbankingnews.com logoPortola Pharmaceuticals Inc (PTLA) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 22 at 4:04 PM
finance.yahoo.com logoPortola Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PTLA-US : May 22, 2017
finance.yahoo.com - May 22 at 9:30 AM
finance.yahoo.com logoPortola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association (EHA)
finance.yahoo.com - May 18 at 9:01 AM
finance.yahoo.com logoETFs with exposure to Portola Pharmaceuticals, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 7:49 PM
americanbankingnews.com logoWilliam Blair Research Analysts Increase Earnings Estimates for Portola Pharmaceuticals Inc (PTLA)
www.americanbankingnews.com - May 11 at 7:52 AM
americanbankingnews.com logoPortola Pharmaceuticals Inc (PTLA) Expected to Post Q2 2017 Earnings of ($1.53) Per Share
www.americanbankingnews.com - May 11 at 7:52 AM
finance.yahoo.com logoPortola Pharmaceuticals, Inc. :PTLA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 11:24 AM
americanbankingnews.com logoPortola Pharmaceuticals Inc (PTLA) Given a $46.00 Price Target by Oppenheimer Holdings Inc. Analysts
www.americanbankingnews.com - May 9 at 11:02 PM
finance.yahoo.com logoPortola Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PTLA) : May 9, 2017
finance.yahoo.com - May 9 at 6:56 PM
globenewswire.com logoPortola Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
globenewswire.com - May 9 at 10:57 AM

Social

Chart

Portola Pharmaceuticals (PTLA) Chart for Wednesday, June, 28, 2017

This page was last updated on 6/28/2017 by MarketBeat.com Staff